Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer

Emeaga Maheswaran1, Christina B. Pedersen1, Henrik J. Ditzel1,2, Morten F. Gjerstorff1*

1 Department of Cancer and Inflammation Research, Institute for Molecular Medicine (IMM), University of Southern Denmark, Odense, Denmark, 2 Department of Oncology, Odense University Hospital, Odense, Denmark

* mgjerstorff@health.sdu.dk

Abstract

Immunotherapy is emerging as a supplement to conventional cancer treatment, and identifying antigen targets for specific types of cancer is critical to optimizing therapeutic efficacy. Cancer/testis antigens are highly promising targets for immunotherapy due to their cancerspecific expression and antigenic properties, but the expression patterns of most of the more than 200 identified cancer/testis antigens in various cancers remain largely uncharacterized. In this study, we investigated the expression of the cancer/testis antigens ADAM2, CALR3 and SAGE1 in lung and breast cancer, the two most frequent human cancers, with the purpose of providing novel therapeutic targets for these diseases. We used a set of previously uncharacterized antibodies against the cancer/testis antigens ADAM2, CALR3 and SAGE1 to investigate their expression in a large panel of normal tissues as well as breast and lung cancers. Staining for the well-characterized MAGE-A proteins was included for comparison. Immunohistochemical staining confirmed previous mRNA analysis demonstrating that ADAM2, CALR3 and SAGE1 proteins are confined to testis in normal individuals. Negative tissues included placenta, which express many other CT antigens, such as MAGE-A proteins. Surprisingly, we detected no ADAM2, CALR3 and SAGE1 in the 67 lung cancers (mainly non-small lung cancer) and 189 breast cancers, while MAGE-A proteins were present in 15% and 7–16% of these tumor types, respectively. Treatment with DNA methyltransferase inhibitors has been proposed as an attractive strategy to increase the expression of cancer/testis antigens in tumors before immunotargeting; however, neither ADAM2, CALR3 nor SAGE1 could be significantly induced in lung and breast cancer cell lines using this strategy. Our results suggest that ADAM2, CALR3 and SAGE1 cancer/testis antigens are not promising targets for immunotherapy of breast and lung cancer.
Introduction

Modulation of the immune system in cancer patients has shown to efficiently generate anti-tumor immune responses, but selection of targets for effective and specific intervention remains challenging. The unique expression pattern and immunogenic properties of cancer/testis (CT) antigens make them ideal targets for different types of cancer immunotherapy, such as vaccination and adoptive transfer with recombinant T-cell receptor-transduced T cells. CT antigens are male germ cell proteins ectopically expressed in various malignancies [1–3]. Male germ cells are devoid of HLA-class I molecules and cannot present antigens to T cells. Therefore, CT antigens can be considered tumor-specific neo-antigens when expressed in tumor cells, and have the capacity to elicit immune responses that are strictly tumor-specific. This is consistent with the frequent observations of cellular and humoral immune responses to CT antigens in cancer patients [4–8]. Thus, cancer/testis antigens suggest the promise of highly specific immunotargeting of human cancers.

More than 200 different CT antigens have been identified (CTDatabase, http://www.cta.lncc.br), but only a small number of these have been investigated for expression profiles. Although some CT antigens tend to be co-expressed in a subset of tumors, others have distinct and cancer-subtype specific expression profiles [9–12]. Thus, it is essential to characterize the expression of more CT antigens to provide additional targets for treatment of different types of human cancer. To this end, we have identified antibodies suitable for immunostaining of the three novel CT antigens ADAM2, CALR3 and SAGE1, and characterized the expression of these proteins in normal tissues and the two most common types of human malignancies, breast and lung cancer.

Materials and Methods

Tissue specimens

Samples of normal tissues (skin, tonsil, esophagus, salivary gland, lung, thyroid, spleen, thymus, liver, gall bladder, kidney, pancreas, cerebellum, uterus, placenta, muscle, testis, prostate, bladder, colon, duodenum, ventricle) were collected as diagnostic specimens from patients treated at the University Hospital of Odense. The ethical committee of Funen and Vejle County (VF20050069) approved the use of these tissues, without informed consent from participants. The lung (LC1502) and breast (BRC1502) carcinoma tissue microarrays were purchased from BioCat GmbH, Heidelberg, Germany. The lung carcinoma tissue microarray LC1502 contained 23 cases of lung squamous cell carcinoma, 21 lung adenocarcinoma, 5 each of lung adenosquamous carcinoma and bronchioalveolar carcinoma, 7 small cell undifferentiated lung carcinoma, 1 each undifferentiated lung carcinoma and malignant mesothelioma, 2 each of large cell lung carcinoma and carcinosarcoma, 3 neuroendocrine lung carcinoma, and 1 each of lung chronic bronchitis, lobar pneumonia and pulmonary tuberculosis, 2 normal lung tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position). The breast carcinoma tissue microarray BRC1502 contained 62 cases of ductal carcinoma, 2 lobular carcinoma and 1 each of papillary carcinoma, sarcoma, mucinous adenocarcinoma and tubular carcinoma. The estrogen receptor and HER2 status of this first cohort of breast cancers were not available. Tissue microarrays of the second cohort of breast cancers with information on receptor status were subsequently analyzed. The generation and characterization of this second cohort has previously been reported [13]. The experiment was conducted in compliance with the Helsinki declaration.

Immunohistochemical staining

Paraffin-embedded, formalin-fixed tissues were cut in 6 μm sections, deparaffinized, treated with 1.5% H2O2 in Tris-buffered saline (pH 7.5) for 10 min to block endogenous peroxidase
activity. Thereafter, they were rinsed in distilled H₂O, demasked, processed for antigen retrieval and washed in TNT buffer (0.1 M Tris, 0.15 M NaCl, 0.05% Tween-20, pH 7.5). To optimize conditions for staining with antibodies raised against amino acids 122–215 of ADAM2 (rabbit polyclonal, HPA026581; Sigma Aldrich, Brondby), amino acids 195–294 of CALR3 (rabbit polyclonal, NBP2-33524, Novus, Littleton, CO, USA) and amino acids 497–641 of SAGE1 (rabbit polyclonal, HPA003208, Sigma Aldrich), different concentrations were tested in combination with different antigen retrieval protocols using sections of human testis. The methods of antigen retrieval included microwave boiling for 15 min in 1) T-EG buffer (10 mM Tris, 0.5 mM EGTA, pH 9.0), 2) 10 mM citrate buffer, pH 6.0 or 3) Dako Target retrieval solution (Dako S1699), or subjected to proteolytic treatment using 4) 0.05% protease type XIV (pronase E, Sigma, cat. no. P5147) in TBS, pH 7.0 for 15 min at 37°C, or 5) 0.4% pepsin (Sigma, cat. no. P7012) in 0.01 M HCl for 20 min at 37°C. A protocol for immunohistochemical staining with mouse anti-MAGE-A (mouse monoclonal, Clone 6C1 Santa Cruz Biotechnology, Heidelberg, Germany; recognizing MAGE-A1, -A2, -A3, -A4, -A6, -A10 and -A12) has previously been described [9]. Primary antibodies were diluted in antibody diluent (S2022, DAKO Cytomation, Glostrup, Denmark) for 1h at room temperature. Sections were washed with TNT and incubated with horseradish peroxidase-conjugated “Ready-to-use” EnVision+ polymer K4001 (DAKO Cytomation) for 30 min, followed by another wash with TNT. The final reaction product was visualized by incubating with 3,3′-diaminobenzidine (DAB)+ substrate-chromogen for 10 min, followed by washing with H₂O and counterstaining of sections with Mayers hematoxylin before mounting in AquaTex (Merck Inc., Whitehouse Station, NJ, USA).

**Histological evaluation**

Tissue sections were evaluated by immunohistochemistry and considered positive if staining was observed in more than 5 cells, regardless of intensity.

**Cell culture**

Breast (MDA-MB-231, MCF-7, T47D) and lung cancer cell lines (HCC827, PC9, A549) were cultured in RPMI or DMEM (Life technologies, Naerum, Denmark) supplemented with 10% fetal bovine serum (Sigma Aldrich), penicillin (100 U/ml) and streptomycin (100 mg/ml). For MCF7 and T47D, 6–8 ng/ml insulin (Sigma Aldrich) was added to the media. When indicated, cells were grown with 5µM 5-Aza-2′-deoxycytidine (Sigma-Aldrich) for 48 hours. Cell lines were obtained from ATCC, Wesel, Germany.

**Quantitative PCR**

Total RNA was purified from cultured cells using Isol-RNA lysis reagent (5 Prime, Hilden, Germany) and RevertAid Premium Reverse Transcriptase kit (Fermentas/Life Technologies) was used for cDNA synthesis with random hexamer primers. Relative quantification of gene expression was performed with SYBR green PCR Mastermix (Applied Biosystems, Nærum, Denmark). PCR primers were: ADAM2 (Qiagen, Copenhagen, Denmark, QT00039130), CALR3 (Qiagen, QTR0036162), SAGE1 (Qiagen, QT00044422) and PUM1 (Qiagen, QT00029421).

**Results and Discussion**

Lung and breast cancer are the two most common types of cancer, and novel therapeutic strategies are needed to optimize clinical treatments. To identify potential targets for immunotherapy of lung and breast cancer, we used a panel of previously uncharacterized antibodies to
investigate the expression of three previously uncharacterized CT antigens, ADAM2, CALR3 and SAGE1, in patient tumors, cancer cell lines and a panel of normal tissues. The antibodies used were expected to detect all variants of the target proteins. For comparison, we included a well-characterized antibody recognizing MAGE-A CT antigens. Conditions for immunohistochemical analysis of ADAM2, CALR3 and SAGE1 were optimized with regard to method of antigen retrieval and antibody concentration using tissue sections of normal testis (see methods for details). Further investigation of ADAM2, CALR3 and SAGE1 in 22 normal tissues demonstrated that these proteins were selectively expressed in testis germ cells (Fig 1). ADAM2 and CALR3 were expressed at the spermatocyte and spermatid stage of spermatogenesis and were both localized at the cell membranes. SAGE1, on the other hand, was limited to the spermatogonia and pre-meiotic spermatocytes and were localized to the nuclei. These results are consistent with previous reports suggesting that chromosome X-encoded CT antigens, such as SAGE-1, are generally expressed in pre-meiotic stages of germ cells, while autosomal-encoded CT antigens, such as ADAM2 and CALR3, are generally expressed in post-meiotic stages of germ cells [12]. No expression of ADAM2, CALR3 and SAGE1 was seen in placenta (consistent with available RT-PCR results from the CTDatabase, http://www.cta.lncc.br), in contrast to MAGE-A (Fig 1) and other CT antigens [12]. These results suggested that ADAM2, CALR3 and SAGE1 were testis-specific in expression and supported previous analyses of mRNA levels in normal tissues [14, 15], further highlighting their potential as specific cancer targets. The importance of targeting antigens with high cancer-specificity has recently been emphasized by two studies with genetically modified T-cell receptors wherein patients died due to unexpected reactivity towards non-cancerous tissues [16–18].

Having established the ability of the antibody reagents to specifically detect ADAM2, CALR3 and SAGE1 CT antigens, we next investigated the expression of these proteins in
primary tumors from patients with different subtypes of lung cancer at different stages. The
panel included 55 non-small cell lung cancers (NSCLC, including squamous cell carcinomas,
adeno-carcinomas, adenosquamous carcinoma, bronchioalveolar carcinoma, undifferentiated
lung carcinoma, mesothelioma, neuroendocrine lung carcinoma and large cell carcinomas),
which constitute about 85% of lung cancers (Table 1; Fig 2). A number of small cell lung can-
cers as well as some more rare lung cancer subtypes were also included in the analysis, however,
the relatively low numbers of samples from these subtype did not allow statistically sound con-
clusions. Surprisingly, we found that none of these tumors expressed any of the three CT anti-
gens. In contrast, 16% (confidence interval; +/-8.8) of the lung cancers (11/67) were positive
for MAGE-A CT antigens, in agreement with earlier studies [9, 19]. Other CT antigens are also
expressed at relatively high frequencies in lung cancer [20, 21]. This is the first report on
ADAM2, CALR3 and SAGE1 expression in lung cancer.

We also investigated the expression of ADAM2, CALR3 and SAGE1 in 13 breast cancer cell
lines (S1 Table) and in breast cancer tumors from two cohorts of patients with data on clinical
stage and receptor status, respectively (Tables 2 and 3). Nuclear staining for SAGE1 was
observed in the breast cancer cell line (MB-MDA-435, debated also to be of melanoma origin,
although the overwhelming studies support it being of breast cancer origin [22]) (Fig 3), while

| Stage | Number of tumors | ADAM2-positive | CALR3-positive | SAGE1-positive | MAGE-A-positive |
|-------|------------------|----------------|----------------|----------------|-----------------|
| I     | 45               | 0              | 0              | 0              | 5 (11%)         |
| II    | 17               | 0              | 0              | 0              | 4 (24%)         |
| IIIa+b| 5                | 0              | 0              | 0              | 2 (40%)         |
| Total | 67               | 0              | 0              | 0              | 11 (16%)        |

Table 1. ADAM2, CALR3, SAGE1 and MAGE-A expression in lung cancer.

![Fig 2. Immunohistochemical staining of CT antigens in lung and breast cancer tumors.](doi:10.1371/journal.pone.0134967.g002)
Table 2. Analysis of ADAM2, CALR3, SAGE1 and MAGE-A expression in cohort 1 consistent of 68 breast cancers of different clinical stages.

| Stage  | Number of tumors | ADAM2-positive | CALR3-positive | SAGE1-positive | MAGE-A-positive |
|--------|------------------|----------------|----------------|----------------|----------------|
| I      | 8                | 0              | 0              | 0              | 0              |
| I-II   | 5                | 0              | 0              | 0              | 0              |
| II     | 26               | 0              | 0              | 0              | 3 (12%)        |
| II-III | 24               | 0              | 0              | 0              | 2 (8%)         |
| III    | 5                | 0              | 0              | 0              | 0              |
| Total  | 68               | 0              | 0              | 0              | 5 (7%)         |

doi:10.1371/journal.pone.0134967.t002

Table 3. Analysis of ADAM2, CALR3 and MAGE-A expression in cohort 2 consisting of 121 breast cancers of different receptor status.

| Receptor status | Number of tumors | ADAM-positive | CALR3-positive | SAGE1-positive | MAGE-A-positive |
|-----------------|------------------|---------------|----------------|----------------|----------------|
| ER-positive     | 18               | 0             | 0              | ND             | 1 (6%)         |
| ER-negative     | 103              | 0             | 0              | ND             | 18 (18%)       |
| HER2-positive   | 40               | 0             | 0              | ND             | 7 (18%)        |
| HER-negative    | 81               | 0             | 0              | ND             | 12 (15%)       |
| ER- and HER2-negative | 70       | 0             | 0              | ND             | 11 (16%)       |
| All             | 121              | 0             | 0              | ND             | 19 (16%)       |

ND = not determined (staining of these tissue arrays with the SAGE1 antibody produced significant background coloration resulting in inconclusive results).

doi:10.1371/journal.pone.0134967.t003

Fig 3. Immunohistochemical staining of SAGE1 in breast cancer and melanoma cell lines. SAGE1 was detected in the nucleus of FM6 and MDA-MB-435, while other cells lines were negative (all pictures magnification x20).

doi:10.1371/journal.pone.0134967.g003
Fig 4. Effect of 5-aza-2'-deoxycytidine-treatent on the expression of CT antigens in lung and breast cancer cell lines. Expression of MAGE-A1, ADAM2, CALR3 and SAGE1 CT antigen genes in 5-aza-2'-deoxycytidine-treated (5 μM, 48 hours) and untreated lung (A) and breast (B) cancer cell lines was measured using quantitative PCR. Error bars = standard deviation.

doi:10.1371/journal.pone.0134967.g004
ADAM2, CALR3 was not detected in this cell line. The remaining breast cancer cell lines and the 189 breast tumors did not express the three CT antigens. MAGE-A CT antigens were expressed in 4/13 cell lines and 7% (+/- 6.1) of primary tumors of different subtypes, comparable to previous studies [23]. MAGE-A CT antigens were more frequently expressed in estrogen receptor-negative tumors (18% +/- 6.9) consistent with other reports [24, 25].

The absence of ADAM2, CALR3 and SAGE1 expression in lung and breast cancer prompted us to test their expression in a panel of melanoma cell lines (S2 Table; Fig 3), since most characterized CT antigens have shown the highest incidence in melanoma among the different types of cancer. SAGE-1 was expressed in 6/17 melanoma cell lines, while ADAM2 and CALR3 were not detected in any of the 17 cell lines (S2 Table).

Infrequent or heterogeneous expression of tumor antigens in tumors may be an obstacle to development of efficient and widely applicable cancer vaccines. Importantly, agents that inhibit the function of DNA methyltransferases have been demonstrated to induce the expression of CT antigen genes. For instance, 5-aza-2'-deoxycytidine activates MAGE-A, GAGE, CT45 and many other CT antigen genes [3, 26–29]. To investigate the possibility of inducing ADAM2, CALR3 and SAGE1 expression in lung and breast cancer cells, we stimulated lung (PC9, HCC827 and A549) and breast cancer cell lines (MCF7, MDA-MB-231 and T47D) with 5-aza-2'-deoxycytidine (Fig 4). Levels of MAGE-A gene expression increased significantly in all cell lines, except for PC9 and A549, which already exhibited high MAGE-A expression. In contrast, neither ADAM2, CALR3 nor SAGE1 expression was significantly increased in any of the cell lines, suggesting that DNMT inhibition cannot potentiate immunotherapy targeting these antigens.

Conclusions
We investigated the potential of three previously uncharacterized CT antigens, ADAM2, CALR3 and SAGE1, as targets for treatment of lung and breast cancer. Although we demonstrated that these CT antigens exhibit a germ cell-specific expression pattern in normal tissues, which is an important feature of antigens for cancer immunotherapy, none of these antigens were expressed in lung and breast cancer. Furthermore, the expression of these antigens could not be induced by DNMT-inhibitor treatment, in contrast to many other CT antigens. In conclusion, ADAM2, CALR3 and SAGE1 should not be considered targets for treatment of lung and breast cancer. However, our study also provides the reagents and conditions for assessing expression of these antigens in other cancer types. Furthermore, SAGE1 was detected in about 40% of melanoma cell lines, suggesting that this protein may be an interesting target. Our study represents an important step in the tedious evaluation of the long list of potential tumor antigens to identify novel therapeutic targets for different types of cancer.

Supporting Information
S1 Table. ADAM2, CALR3, SAGE1 and MAGE-A expression in breast cancer cell lines. (DOCX)
S2 Table. ADAM2, CALR3, SAGE1 and MAGE-A expression in melanoma cells lines. (DOCX)

Acknowledgments
We thank Lisbet Mortensen and Ole Nielsen for excellent technical assistance with the immunohistochemical analysis and M. K. Occhipinti for editorial assistance. This study was supported by the Danish Research Council, the Danish Cancer Society and the Danish Cancer Research Foundation.
Author Contributions
Conceived and designed the experiments: EM CBP HJD MFG. Performed the experiments: EM CBP MFG. Analyzed the data: EM CBP HJD MFG. Contributed reagents/materials/analysis tools: HJD MFG. Wrote the paper: EM HJD MFG.

References
1. Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015.
2. Luftl M, Schuler G, Jungbluth AA. Melanoma or not? Cancer testis antigens may help. The British journal of dermatology. 2004; 151(6):1213–8. PMID:15606517.
3. Gjerstorff MF, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert opinion on biological therapy, 2010; 10(7):1061–75. Epub 2010/04/28. doi: 10.1517/14712598.2010.485188 PMID: 20420535.
4. Gnajatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(15):8862–7. PMID:12853579.
5. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoff M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. The Journal of experimental medicine. 1998; 187(2):265–70. PMID:9432985.
6. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnajatic S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. Journal of immunology. 2009; 183(7):4800–8. Epub 2009/09/08. doi:10.4049/jimmunol.0900903 PMID: 19734225.
7. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, et al. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer research. 2003; 63(17):5601–6. Epub 2003/09/23. PMID:15400410.
8. Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, et al. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. International journal of cancer Journal international du cancer. 2012; 131(6):E649–58. Epub 2011/11/24. doi:10.1002/ijc.27359 PMID: 22109656.
9. Gjerstorff MF, Johansen LE, Nielsen O, Keck K, Ditzel HJ. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. British journal of cancer. 2006; 94(12):1864–73. PMID:16773077.
10. Gjerstorff MF, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue antigens. 2012; 80(6):523–7. Epub 2012/11/10. doi:10.1111/tan.12015 PMID:23137323.
11. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. International journal of cancer Journal international du cancer. 2005; 115(6):960–6. PMID:15791093.
12. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nature reviews Cancer. 2005; 5(8):615–25. PMID: 16034368.
13. Ehmnsen S, Hansen LT, Bak M, Brasch-Andersen C, Ditzel HJ, Leth-Larsen R. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. International journal of cancer Journal international du cancer. 2015. doi:10.1002/ijc.29582 PMID:25912829.
14. Hayashi E, Matsuizaki Y, Hasegawa G, Yaguchi T, Kurihara S, Fujita T, et al. Identification of a novel cancer-tests antigen CRT2 frequently expressed in various cancers using representational differential analysis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(21):6267–74. doi: 10.1158/1078-0432.CCR-07-1374 PMID: 17975137.
15. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer research. 2000; 60(14):3848–55. PMID:10919659.
16. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of immunotherapy. 2013; 36(2):133–51. doi:10.1097/CJI.0b013e3182829903 PMID: 23377666; PubMed Central PMCID: PMC33581623.
17. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122
18. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science translational medicine. 2013; 5(197):197ra03. doi:10.1126/scitranslmed.3006034 PMID: 23926201.

19. Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. International journal of cancer Journal international du cancer. 2011; 129(5):1137–48. doi: 10.1002/ijc.21710496.

20. Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, et al. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget. 2015; 6(5):2812–26. PMID: 25739119.

21. Gjerstorff MF, Pohl M, Olsen KE, Ditzel HJ. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC cancer. 2013; 13:466. doi:10.1186/1471-2407-13-466 PMID: 24103781; PubMed Central PMCID: PMC3851761.

22. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer research. 2009; 69(13):5292–3. doi: 10.1158/0008-5472.CAN-09-1528 PMID: 19549886.

23. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer research. 2001; 61(18):6682–7. PMID: 1159535.

24. Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielanga V, Kroman N, et al. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Molecular & cellular proteomics: MCP. 2013; 12(2):381–94. doi:10.1074/mcp.M112.019786 PMID: 23172894; PubMed Central PMCID: PMC3567861.

25. Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielanga V, Kroman N, et al. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Molecular & cellular proteomics: MCP. 2013; 12(2):381–94. doi:10.1074/mcp.M112.019786 PMID: 23172894; PubMed Central PMCID: PMC3567861.

26. Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S, et al. Characterization and expression of CT45 in Hodgkin’s lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(16):4804–11. PMID: 16914565.

27. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-2’-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer immunology, immunotherapy: CII. 2009; 58(4):589–601. PMID: 18791715. doi: 10.1007/s00262-008-0582-6

28. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer research. 2000; 60(6):1654–62. PMID: 10749136.

29. Bazhin AV, Wiedemann N, Schnolzer M, Schadendorf D, Eichmuller SB. Expression of GAGE family proteins in malignant melanoma. Cancer letters. 2007; 251(2):258–67. PMID: 17194529.